BACKGROUND: Tumor necrosis factor (TNF)-α and interleukin (IL)-1β are pro-inflammatory cytokines, causing myocardial dysfunction and a negative inotropic effect. The drugs used to treat heart failure affect the production of cytokines. Digoxin, on which this study was focused, is one of the drugs for the treatment of heart failure.

Aim: The present study was designed to examine the early effects of high doses of digoxin on the production of cytokines in healthy dogs.

Methods: Digoxin was given parenterally to dogs at 0.15 mg/kg. IL-1β and TNF-α production and levels of digoxin in the serum were measured 0, 12, 24, 48, and 72 h following administration of digoxin.

Results: As the levels of serum digoxin taken at 12, 24, 48, and 72 h of administration were considered significantly high compared with preceding values (p < 0.001), no notable change in serum IL-1β and TNF-α levels was observed.

Conclusions: These results suggest that high doses of digoxin do not cause a significant cytokine production in heart muscle in the early phase.

Key words: High dose, Digoxin, Cytokines

Introduction

Tumor necrosis factor (TNF)-α and interleukin (IL)-1β are pro-inflammatory cytokines, causing myocardial dysfunction and a negative inotropic effect. The drugs used to treat heart failure affect the production of cytokines. Digoxin, on which this study was focused, is one of the drugs for the treatment of heart failure.1,2 Tumor necrosis factor (cachectin) is a pluripotent cytokine, produced primarily by monocytes, that has been shown experimentally to cause fever and hypotension. Elevated circulating levels of TNF have been noted in patients with a variety of neoplastic, infectious, and collagen vascular disorders, many of which are characterized by severe weight loss and anorexia.3

In normal doses, digoxin has a positive effect on heart function via inhibition of sodium/potassium ATPase or indirectly via the sympathetic nerve and kidneys. Digoxin is one of the most commonly prescribed drugs for the treatment of heart failure, and efficacy of digoxin in patients with heart failure and atrial fibrillation is clear. However, this efficacy in patients with heart failure and sinus rhythm has not been established. Digoxin has no significant effect on mortality. Several recent short-term, randomized trials indicated that withdrawing digoxin worsens functional status, exercise capacity, and the left ventricular ejection fraction in patients with heart failure, but there is uncertainty about its efficacy and safety.4,5

We hypothesized that negative effects by high doses of digoxin could be achieved by the release of cytokines. This study was designed to examine the early effects of high doses of digoxin on the production of cytokines in healthy dogs.

Materials and methods

Healthy dogs were used for the present study. Ten dogs were included in the study. The study was approved by an internal ethical review board. Digoxin was given parenterally at 0.15 mg/kg, which is fivefold higher than the usual therapeutic dose. It is difficult to compare dosages in different animal species; however, on the basis of the body surface area, a given dosage in dogs is comparable with a dosage about four-fold lower in humans. Thus, a dosage of 0.03 mg/kg of digoxin in dogs is equivalent to 0.008 mg/kg in humans, which is a therapeutic dose.2 None of these dogs died. A total of 5 ml of venous blood was drawn from each dog at 12, 24, 48, and 72 h following administration of digoxin. Blood samples were then centrifuged at 2000 rpm for 10 min in a refrigerated centrifuge to separate serum samples from the cells. Serum samples were stored at −70°C in plastic tubes until the analysis. IL-1β and TNF-α production and levels of digoxin in the serum samples were measured.

Serum digoxin, IL-1β and TNF-α was measured using commercial kits, which are a solid-phase, two-site
chemiluminescent immunometric assay (Immullite; DPC, Los Angeles, USA). Performance data for digoxin, IL-1β and TNF-α, respectively, are as follows: calibration ranges, 0.5–8 ng/ml, up to 1000 pg/ml, and up to 1000 pg/ml; analytical sensitivities, 0.1 ng/ml, 1.5 pg/ml, and 1.7 pg/ml; intra-assay coefficients of variation, 4.4% at a concentration of 1.6 ng/ml, 2.8% at a concentration of 39 pg/ml, and 3.5% at a concentration of 34 pg/ml; inter-assay coefficients of variation, 9.4% at a concentration of 1.6 ng/ml, 7.7% at a concentration of 13 pg/ml, and 6.5% at a concentration of 17 pg/ml; linearity, 94% at a dilution of 2 in 5, 95% at a dilution of 4 in 8, and 90% at a dilution of 4 in 8; and recoveries, average 109%, 102%, and 99%.

The obtained data were analyzed by Wilcoxon's rank sum tests.

**Results**

Digoxin, IL-1β and TNF-α values obtained before and after administration of digoxin are presented in Table 1.

As the levels of serum digoxin observed at 12, 24, 48, and 72 h following the administration of digoxin are presented in Table 1.

Although the effect of IL-1 on cardiac function remains controversial, it has been shown to decrease cardiac contractility. More recently, IL-1β has been found to cause myocyte hypertrophy associated with the induction of fetal genes. Another recent study has reported that the chronic infusion of TNF-α in rats produces left ventricular contractile dysfunction and dilatation. Transgenic overexpression of TNF-α in the heart, using the cardiac-specific α-myosin heavy chain promoter, has just been reported to cause systolic dysfunction, myocarditis, ventricular dilatation, and the development of heart failure. Furthermore, another transgenic line expressing lower levels of cardiac TNF-α caused dilated cardiomyopathy without prominent inflammation. Thus, available data pertaining to cardiac transgenic overexpression of TNF-α point to a direct relation between cytokine concentrations and inflammatory response or mortality. TNF-α is a pro-inflammatory cytokine that produces left ventricular dysfunction and a negative inotropic effect in cardiac tissue when it is overexpressed in human subjects. Previous studies have shown that levels of circulating TNF-α are elevated in patients with advanced congestive heart failure, and especially in those with cardiac cachexia.

In the present study, in the result of administration of a five-fold higher dose of digoxin, no increase in IL-1β and TNF-α levels was observed.

**Discussion**

In previous studies, it was reported that IL-1β and TNF-α levels were increased in patients with heart failure. In the present study, we planned to investigate the effect of high dose digoxin on IL-1β and TNF-α levels in healthy subjects without any previous heart failure, thereby using healthy dogs.

Each cytokine that shows various features is synthesized by special cell types to be a response to a specific stimulus. TNF and IL-1 are mediators of natural immunity and they are synthesized by mononuclear phagocytes.

Cytokines are now being considered important factors in the pathogenesis and pathophysiologically of heart failure. High levels of circulating cytokines have been reported in patients with heart failure, and various cytokines have been shown to depress myocardial contractility in vitro and in vivo. Although the effect of IL-1 on cardiac function

### Table 1. The values of digoxin, IL-1β and TNF-α obtained before and after administration of digoxin

|                  | 0 h (control) | 12 h | 24 h | 48 h | 72 h |
|------------------|--------------|------|------|------|------|
| Digoxin (ng/ml)  | 0.8 ± 0.14   | 12.0 ± 1.29* | 7.8 ± 0.53* | 3.7 ± 0.22* | 3.0 ± 0.31* |
| IL-1β (pg/ml)    | 0.9 ± 0.35   | 1.1 ± 0.11  | 0.9 ± 0.13  | 0.9 ± 0.19  | 0.4 ± 0.10  |
| TNF-α (pg/ml)    | 3.4 ± 0.64   | 4.0 ± 0.50  | 3.1 ± 0.45  | 3.2 ± 0.44  | 3.3 ± 0.47  |

* p < 0.001.
This may have caused us to not observe any notable results in the present study, but we think that if much higher doses of digoxin had been used in this study, much more notable results would have been observed. Second, the present study was performed only on healthy dogs. The effect of digoxin may of course be different both in healthy dogs and in dogs with heart failure. In fact, Matsumori et al. showed that high doses of digoxin increased the serum IL-1β and TNFα levels in mice with heart failure developed by viral myocarditis.

In the present study, serum TNFα and IL-1β levels were no different from those of the controls. These results may suggest that high-dose digoxin might not causes a significant cytokine production in early phase. But our results need to be supported with further studies with longer or different doses of digoxin treatment.

ACKNOWLEDGEMENTS. The authors are extremely thankful to Ayten Babacan, B.A., the lecturer for Medical English at the School of Medicine, University of Yüzünce Yil, for her correction in the redaction of this paper.

References

1. Levine B, Kalman J, Mayer L, Filiot HM, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236–241.
2. Matsumori A, Igarashi H, Ono K, Iwasaki A, Miyamoto T, Nishio R, Sasayama S. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999; 63: 934–940.
3. Giradin E, Grav GE, Dayer JM, Roux-Lombard P. J5 Study Group, Lambert PH. Tumour necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1998; 319: 397–400.
4. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533.
5. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure; results of the PROVED Trial. J Am Coll Cardiol 1993; 22: 955–962.
6. Abbas Abul K. Cellular and Molecular Immunology. 2nd edn. Pennsylvania: WB. Saunders Company, 1994; 239–260.
7. Yokoyama T, Yama LC, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factorα in the adult mammalian heart. J Clin Invest 1995; 92: 2503–2512.
8. Evans HG, Lewis MJ, Shah AM. Interleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 1993; 27: 1486–1490.
9. Thaik CM, Calderone A, Takahashi N, Colucci S. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96: 1094–1099.
10. Bozkurt B, Kribbs SB, Chahh FJ Jr, Michael LH, Didenko VV, Hornsey PL, et al. Pathophysiologically relevant concentrations of tumor necrosis factorα promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382–1391.
11. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factorα. Circulation 1998; 97: 1375–1381.
12. Kubota T, McTieren CE, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific over-expression of tumor necrosis factorα. Circ Res 1997; 81: 627–635.
13. Bristow MR. Tumor necrosis factorα and cardiomyopathy. Circulation 1998; 97: 1340–1342.
14. Parisot JT, Venetsanou KE, Mentzakou DG, Zirias NG, Kefalas CG, Karas SM. Tumor necrosis factor-alfa serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure. Scand Cardiovasc J 1999; 33: 344–350.
15. Matsumori A, Ono K, Nishio R, Igarashi H, Shoji T, Matsui S, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997; 96: 1501–1506.